Intercell AG

Intercell AG wins the Scrip Award for Biotech Company of the Year

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@


Wien (euro adhoc) - Vienna (Austria), December 11, 2008 - Intercell AG (VSE: ICLL) announced today that the Company has been awarded the Scrip Award for Biotech Company of the Year at last night's ceremony at the London Hilton, Park Lane.

The Scrip Awards are voted for by a panel of esteemed judges from the pharmaceutical industry worldwide. The judging criteria included the Company´s pipeline, fund raising and cash position, licensing and partnership deals, and technology.

Vaccine developer Intercell was awarded this prize in recognition of its achievements in 2008 which include the acquisition of Iomai Corporation, reaching its first profitable full year, the alliance with Novartis as well as Intercell's prophylactic Japanese Encephalitis vaccine making significant progress towards its market approval.

CEO of Intercell, Gerd Zettlmeissl, said: "We are delighted to be awarded the title of Biotech Company of the Year in recognition of our hard work and progress. This has been a great year for Intercell in many aspects and we are very positive looking towards 2009."

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: